» Articles » PMID: 29742512

LncRNA MT1JP Suppresses Gastric Cancer Cell Proliferation and Migration Through MT1JP/MiR-214-3p/RUNX3 Axis

Overview
Date 2018 May 10
PMID 29742512
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Emerging evidence points towards an important role of long noncoding RNAs (lncRNAs) in the tumorigenesis and progression of gastric cancer (GC). MT1JP has recently been reported to be differentially expressed and act as a tumor suppressor in different tumors, with its mechanisms not fully understood in GC.

Methods: RT-qPCR was used to detect the expression of MT1JP, miR-214-3p and RUNX3 in tumor tissues and cell lines of GC. The CCK-8 assay, colony formation, Transwell assay and wound healing assay were used to evaluate the proliferation, invasion and migration of GC cells, respectively. Bioinformatics analysis and luciferase reporter assay were performed to disclose the interaction between MT1JP, miR-214-3p and RUNX3. Western blot and immunofluorescence were applied to assess the downstream signaling of RUNX3.

Results: MT1JP was found downregulated in GC tissues and cells. Low expression of MT1JP was significantly correlated with advanced TNM stage and lymphatic metastasis. The expression of plasma MT1JP was also found decreased in GC patients compared to healthy controls, with an area under the ROC curve (AUC) of 0.649 for diagnosis of GC. Gain- and loss-of-function of MT1JP revealed that MT1JP functioned as a ceRNA for miR-214-3p to facilitate RUNX3 expression and then upregulated p21 and Bim levels suppressing GC cell proliferation, invasion and migration, and promoting apoptosis. Furthermore, MT1JP overexpression suppressed tumor growth and inhibited the expression of miR-214-3p and proliferation antigen Ki-67, but increased the expression of RUNX3, p21 and Bim in vivo.

Conclusions: Our results suggest a potential ceRNA regulatory network involving MT1JP regulates RUNX3 expression by competitively binding endogenous miR-214-3p in tumorigenesis and progression of GC. This mechanism may contribute to a better understanding of GC pathogenesis and provide potential therapeutic strategy for GC.

Citing Articles

Construction of a potential long noncoding RNA prognostic model involved competitive endogenous RNA for patients with gastric cancer.

Xi T, Zhou Y, Ma S, Lu W, Sun Y, Sun C Medicine (Baltimore). 2024; 103(24):e38458.

PMID: 38875399 PMC: 11175963. DOI: 10.1097/MD.0000000000038458.


Role of non-coding RNAs as new therapeutic targets in regulating the EMT and apoptosis in metastatic gastric and colorectal cancers.

Ebrahimi N, Hakimzadeh A, Bozorgmand F, Speed S, Manavi M, Khorram R Cell Cycle. 2023; 22(20):2302-2323.

PMID: 38009668 PMC: 10730205. DOI: 10.1080/15384101.2023.2286804.


The Functions and Mechanisms of Long Non-coding RNA SNHGs in Gastric Cancer.

Liu S, Rong Y, Tang M, Zhao Q, Li C, Gao W Comb Chem High Throughput Screen. 2023; 27(18):2639-2653.

PMID: 37842903 DOI: 10.2174/0113862073268591230928100922.


Clinical and prognostic significance of long non-coding RNA CRNDE expression in severe pneumonia and its correlation with inflammatory factor levels.

Peng M, Ma L Am J Transl Res. 2023; 15(3):1798-1806.

PMID: 37056853 PMC: 10086886.


Long noncoding RNA BBOX1-AS1 promotes the progression of gastric cancer by regulating the miR-361-3p/Mucin 13 signaling axis.

Cai T, Peng B, Hu J, He Y Bioengineered. 2023; 13(5):13407-13421.

PMID: 36700475 PMC: 9275992. DOI: 10.1080/21655979.2022.2072629.